WASHINGTON — Under a new proposal, the Medicare program would pay for expensive new cancer therapies known as CAR-T for patients across the country.

The Centers for Medicare and Medicaid Services on Friday released a so-called national coverage determination for the therapies that lays out exactly when, and for whom, Medicare will cover a given drug. The proposal specifies that Medicare will cover all FDA-approved CAR-T therapies as long as data is collected about how the patients fare, which could inform the government’s policies about paying for the therapy in the future.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • What may be lost in this is the likelihood that CAR T will become a 3rd line therapy and generally replace the need for Bone Marrow Transplant. The latter is quite expensive and has overall poor survival. In patients failing on this, you will see repeated transplants and multiple admissions for infections. Screening and getting Donors also adds to the costs, as does follow up studies.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy